The short answer
A conflict of interest statement tells you who paid, who was employed, and who held stock. It does not tell you whether a paper is right. The useful move is to identify the judgement calls only the authors could make and weigh those against the declared interest.
Key facts
- Worked example
- Ciudin et al., Adv Ther 2026 (PMID 41820778)
- Funding statement
- Sponsored by Eli Lilly, which also funded rapid service and open access fees
- Employee authors
- 5 of 9 declared as employees and shareholders of Eli Lilly
- Contracted authors
- 3 employed by Costello Medical, paid by Lilly for analytical services
- Independent author
- 1, declaring honoraria from four companies including Lilly
- Medical writing
- Costello Medical, funded by Eli Lilly
- Drug favoured by result
- Tirzepatide, marketed by Eli Lilly
- Data availability
- From the corresponding author on reasonable request
What the statement actually contains
Take the 2026 Bayesian network meta-analysis of tirzepatide, semaglutide and liraglutide as a worked example, because its declarations are unusually complete. The funding statement says the study was sponsored by Eli Lilly and that Lilly also paid the journal's rapid service and open access fees. The conflict of interest section names five authors as employees and shareholders of Eli Lilly and Company, three as employees of Costello Medical which received payment from Lilly for analytical services for this study, and one (the lead author, a clinician) as receiving honoraria from AstraZeneca, Boehringer Ingelheim, Lilly and Novo Nordisk. A separate acknowledgement names the medical writing and statistical support, also at Costello Medical, also funded by Lilly. The result favours tirzepatide, which is Lilly's product.
Why complete disclosure is a good sign, not a bad one
It is tempting to treat a long conflicts section as a warning. It is closer to the opposite. Everything above is knowable only because the paper states it, in a standard place, in plain language. The papers that deserve concern are the ones where the funding is vague, the writing assistance is unacknowledged, or the analytical contractor is invisible. A disclosure this granular gives the reader what they need to scrutinise the work, and the reader's job is to use it rather than to treat it as a verdict.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What sponsorship does and does not predict
There is a substantial literature showing that industry-sponsored studies more often report conclusions favourable to the sponsor than independently funded studies of the same questions. That is an association across bodies of literature, and it is a legitimate reason to apply extra scrutiny to any single sponsored paper. It is not a finding about any individual study, and treating it as one is a category error: it would require discarding most of the evidence base for most licensed medicines, since pivotal trials are almost universally sponsor-funded.
Locate the discretionary decisions
The more useful question is where a sponsor's preference could have entered, rather than whether the work was sponsored. In a randomised trial, most of the structure is fixed in a protocol and registered in advance, which constrains discretion considerably. In a meta-analysis the discretion is much larger and sits in the inclusion criteria: this analysis identified 42 randomised trials and included six. Which six is the single most consequential decision in the paper, it was made by the analysts, and it is where scrutiny belongs. The stated reason, a heterogeneity assessment requiring comparable design, population, background therapy and estimands, is a legitimate one, and the six trials are named so the reasoning can be checked against the supplementary material.
Then look for the external check
The strongest response to a conflict of interest is corroboration. This analysis estimated tirzepatide 15 mg at 6.26 percentage points better than semaglutide 2.4 mg on weight. SURMOUNT-5, a head-to-head trial the authors state was published after their analysis was conducted and which they excluded, found 6.5 percentage points. SURMOUNT-5 was itself Lilly-funded, so that is not fully independent corroboration. It is, however, a prospectively randomised, registered comparison rather than an analyst's reconstruction, and the agreement is close. Independent real-world cohorts point the same direction with smaller effects. Convergence from designs with different biases counts for more than any declaration.
A short procedure
Read the funding statement and the conflicts section before the results, so the results do not colour how you read them. Identify who employed the analysts as distinct from who employed the clinicians. Find the decisions that were discretionary rather than protocol-bound. Check whether those decisions are documented well enough to audit. Then look for whether anything with a different set of biases agrees. If the answer to the last two is yes, the declared interest is information you hold rather than a reason to discard the work.
Frequently asked questions
Should I ignore industry-funded research?
No, and it is not practical to. Almost all pivotal drug trials are sponsor-funded, because almost nobody else funds them. The realistic approach is to read them with their sponsorship known and to weight corroboration from differently biased sources heavily.
Where do I find these statements?
In the paper itself, usually under Declarations, Funding, or Conflict of Interest near the end, and in the full text rather than the abstract. Abstract-only reading is how most conflicts go unnoticed, because the abstract never carries them.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedCiudin A et al., Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis - Adv Ther 2026 (PMID 41820778)pubmed.ncbi.nlm.nih.gov
- PubMedAronne LJ et al., Tirzepatide as Compared with Semaglutide for the Treatment of Obesity - NEJM 2025 (PMID 40353578)pubmed.ncbi.nlm.nih.gov
- PubMedComparative effectiveness of tirzepatide and semaglutide for obesity management in US clinical practice: a 6-month retrospective cohort study - J Endocrinol Invest 2026 (PMID 41661445)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- GDF15: The Same Signal, Wanted and FearedGDF15 acts on a brainstem receptor to suppress appetite. It is an obesity drug target, a cachexia drug target, and a cause of nausea and vomiting in pregnancy.
- PYY(3-36): The Satiety Signal Scaled to the MealPYY is released from the gut after eating, in proportion to the calories consumed. Its active form is produced by the very same enzyme that destroys GLP-1.
- Leptin: The Discovery That Did Not Become a DrugLeptin took wild-type mice from 12.2% body fat down to 0.7%. It is licensed today for a rare disease affecting a few thousand people, and not for obesity.
- The Only Gut Hormone That Makes You Eat, and What Switches It OffGhrelin is the one circulating gut hormone that stimulates feeding. LEAP2, discovered in 2017, is its endogenous antagonist and moves in the opposite direction.
- There Is No Amylin Receptor GeneThe amylin receptor is not its own protein. It is the calcitonin receptor plus an accessory protein, and which accessory decides what the receptor recognises.